A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone

Eric Ueda, Ugur Ozerdem, Yen-Hao Chen, Min Yao, Tzu Huang Kuang, Huiqin Sun, Manuela Martins-Green, Paolo Bartolini, Ameae M. Walker

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

S179D prolactin (PRL) is an experimentally useful mimic of naturally phosphorylated human prolactin. S179D PRL, but not unmodified PRL, was found to be anti-angiogenic in both the chorioallantoic membrane and corneal assays. Further investigation using human endothelial in vitro models showed reduced cell number, reduced tubule formation in Matrigel, and reduced migration and invasion, as a function of treatment with S179D PRL. Analysis of growth factors in human endothelial cells in response to S179D PRL showed: a decreased expression or release of endogenous PRL, heme-oxygenase-1, basic fibroblast growth factor (bFGF), angiogenin, epidermal growth factor and vascular endothelial growth factor; and an increased expression of inhibitors of matrix metalloproteases. S179D PRL also blocked signaling from bFGF in these cells. We conclude that this molecular mimic of a pituitary hormone is a potent anti-angiogenic protein, partly as a result of its ability to reduce utilization of several well-established endothelial autocrine growth loops, partly by its ability to block signaling from bFGF and partly because of its ability to decrease endothelial migration. These findings suggest that circulating levels of phosphorylated PRL may influence the progression of cancer and, furthermore, that S179D PRL may be a useful anti-angiogenic therapeutic.

Original languageEnglish (US)
Pages (from-to)95-111
Number of pages17
JournalEndocrine-Related Cancer
Volume13
Issue number1
DOIs
StatePublished - Mar 1 2006

Fingerprint

Prolactin
Hormones
Fibroblast Growth Factor 2
Angiogenic Proteins
Chorioallantoic Membrane
Heme Oxygenase-1
Pituitary Hormones
Metalloproteases
Epidermal Growth Factor
Vascular Endothelial Growth Factor A
Intercellular Signaling Peptides and Proteins
Endothelial Cells
Cell Count
Growth

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Ueda, E., Ozerdem, U., Chen, Y-H., Yao, M., Kuang, T. H., Sun, H., ... Walker, A. M. (2006). A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocrine-Related Cancer, 13(1), 95-111. https://doi.org/10.1677/erc.1.01076

A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. / Ueda, Eric; Ozerdem, Ugur; Chen, Yen-Hao; Yao, Min; Kuang, Tzu Huang; Sun, Huiqin; Martins-Green, Manuela; Bartolini, Paolo; Walker, Ameae M.

In: Endocrine-Related Cancer, Vol. 13, No. 1, 01.03.2006, p. 95-111.

Research output: Contribution to journalArticle

Ueda, E, Ozerdem, U, Chen, Y-H, Yao, M, Kuang, TH, Sun, H, Martins-Green, M, Bartolini, P & Walker, AM 2006, 'A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone', Endocrine-Related Cancer, vol. 13, no. 1, pp. 95-111. https://doi.org/10.1677/erc.1.01076
Ueda, Eric ; Ozerdem, Ugur ; Chen, Yen-Hao ; Yao, Min ; Kuang, Tzu Huang ; Sun, Huiqin ; Martins-Green, Manuela ; Bartolini, Paolo ; Walker, Ameae M. / A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. In: Endocrine-Related Cancer. 2006 ; Vol. 13, No. 1. pp. 95-111.
@article{dbaed75a6ef14e83a64b47a0239b7104,
title = "A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone",
abstract = "S179D prolactin (PRL) is an experimentally useful mimic of naturally phosphorylated human prolactin. S179D PRL, but not unmodified PRL, was found to be anti-angiogenic in both the chorioallantoic membrane and corneal assays. Further investigation using human endothelial in vitro models showed reduced cell number, reduced tubule formation in Matrigel, and reduced migration and invasion, as a function of treatment with S179D PRL. Analysis of growth factors in human endothelial cells in response to S179D PRL showed: a decreased expression or release of endogenous PRL, heme-oxygenase-1, basic fibroblast growth factor (bFGF), angiogenin, epidermal growth factor and vascular endothelial growth factor; and an increased expression of inhibitors of matrix metalloproteases. S179D PRL also blocked signaling from bFGF in these cells. We conclude that this molecular mimic of a pituitary hormone is a potent anti-angiogenic protein, partly as a result of its ability to reduce utilization of several well-established endothelial autocrine growth loops, partly by its ability to block signaling from bFGF and partly because of its ability to decrease endothelial migration. These findings suggest that circulating levels of phosphorylated PRL may influence the progression of cancer and, furthermore, that S179D PRL may be a useful anti-angiogenic therapeutic.",
author = "Eric Ueda and Ugur Ozerdem and Yen-Hao Chen and Min Yao and Kuang, {Tzu Huang} and Huiqin Sun and Manuela Martins-Green and Paolo Bartolini and Walker, {Ameae M.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1677/erc.1.01076",
language = "English (US)",
volume = "13",
pages = "95--111",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "1",

}

TY - JOUR

T1 - A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone

AU - Ueda, Eric

AU - Ozerdem, Ugur

AU - Chen, Yen-Hao

AU - Yao, Min

AU - Kuang, Tzu Huang

AU - Sun, Huiqin

AU - Martins-Green, Manuela

AU - Bartolini, Paolo

AU - Walker, Ameae M.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - S179D prolactin (PRL) is an experimentally useful mimic of naturally phosphorylated human prolactin. S179D PRL, but not unmodified PRL, was found to be anti-angiogenic in both the chorioallantoic membrane and corneal assays. Further investigation using human endothelial in vitro models showed reduced cell number, reduced tubule formation in Matrigel, and reduced migration and invasion, as a function of treatment with S179D PRL. Analysis of growth factors in human endothelial cells in response to S179D PRL showed: a decreased expression or release of endogenous PRL, heme-oxygenase-1, basic fibroblast growth factor (bFGF), angiogenin, epidermal growth factor and vascular endothelial growth factor; and an increased expression of inhibitors of matrix metalloproteases. S179D PRL also blocked signaling from bFGF in these cells. We conclude that this molecular mimic of a pituitary hormone is a potent anti-angiogenic protein, partly as a result of its ability to reduce utilization of several well-established endothelial autocrine growth loops, partly by its ability to block signaling from bFGF and partly because of its ability to decrease endothelial migration. These findings suggest that circulating levels of phosphorylated PRL may influence the progression of cancer and, furthermore, that S179D PRL may be a useful anti-angiogenic therapeutic.

AB - S179D prolactin (PRL) is an experimentally useful mimic of naturally phosphorylated human prolactin. S179D PRL, but not unmodified PRL, was found to be anti-angiogenic in both the chorioallantoic membrane and corneal assays. Further investigation using human endothelial in vitro models showed reduced cell number, reduced tubule formation in Matrigel, and reduced migration and invasion, as a function of treatment with S179D PRL. Analysis of growth factors in human endothelial cells in response to S179D PRL showed: a decreased expression or release of endogenous PRL, heme-oxygenase-1, basic fibroblast growth factor (bFGF), angiogenin, epidermal growth factor and vascular endothelial growth factor; and an increased expression of inhibitors of matrix metalloproteases. S179D PRL also blocked signaling from bFGF in these cells. We conclude that this molecular mimic of a pituitary hormone is a potent anti-angiogenic protein, partly as a result of its ability to reduce utilization of several well-established endothelial autocrine growth loops, partly by its ability to block signaling from bFGF and partly because of its ability to decrease endothelial migration. These findings suggest that circulating levels of phosphorylated PRL may influence the progression of cancer and, furthermore, that S179D PRL may be a useful anti-angiogenic therapeutic.

UR - http://www.scopus.com/inward/record.url?scp=33646016582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646016582&partnerID=8YFLogxK

U2 - 10.1677/erc.1.01076

DO - 10.1677/erc.1.01076

M3 - Article

C2 - 16601282

AN - SCOPUS:33646016582

VL - 13

SP - 95

EP - 111

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 1

ER -